Kornimate/medical-research-clean huggingface dataset:
radiochemotherapy in elderly patients with oesophagus cancer

Conditions: Esophagus Cancer

Summary: phase ii study of radiochemotherapy for elderly patients with oesophagus cancer.

phase ii study of radiochemotherapy for elderly patients with oesophagus cancer with radiotherapy = 50 gy, 2gy/f ans chemotherapy with 2 arms arm cisplatin = cisplatin 75mg/m2 j1j22 or arm oxaliplatine = oxaliplatine 85mg/m2 every 2 weeks.

Eligibility criteria:
inclusion criteria: * patients aged 75 or more with oesophagus cancer (squamous or adenocarcinoma), fit to treat exclusion criteria: * previous radiotherapy * no fit to treat
a study to evaluate the safety, tolerability, pk, and pd properties of prx-115 in adult volunteers with elevated uric acid levels

Conditions: Gout

Summary: this is a phase 1, double-blind, placebo-controlled, single ascending dose study in participants with elevated uric acid levels. this study will be conducted in approximately 64 adult male and female participants in the dose escalation phase.

participants will be assigned to 1 of 8 sequential dosing cohorts, each composed of 8 participants (6 active + 2 placebo) who will receive a single dose of prx-115 or placebo by intravenous (iv) infusion.

Eligibility criteria:
inclusion criteria: 1. males or females 18 to 65 years of age, inclusive. 2. serum uric acid greater than 6.0 mg/dl (0.35 mmol/l) at the screening visit. 3. body mass index within the range 18.5 to 40 kg/m\^2, inclusive, at the screening visit. 4. women of childbearing potential may be included only if they have a negative beta human chorionic gonadotropin (β-hcg) test result at screening. 5. men and women of childbearing potential and their partners should use double barrier contraception. exclusion criteria: 1. has any condition known to have arthritis as a clinical manifestation 2. had greater than or equal to 1 gout flare in the last year prior to either screening or day -1. 3. has clinical evidence of subcutaneous tophi at either screening or day -1. 4. estimated glomerular filtration rate (egfr) value less than or equal to 60 ml/min/1.73m\^2 5. history of significant renal disease, and/or presence of renal stones at either screening or day -1. 6. has a history of anaphylaxis, severe allergic reactions, or severe atopy. 7. history of autoimmune disorders, and/or participant is immunocompromised or treated with immunosuppressive medications. 8. has evidence of cardiovascular or cerebrovascular disease. 9. history of congestive heart failure, new york heart association class iii or iv. 10. bp outside the range of 90 to 150 mm hg for systolic or 50 to 95 mm hg for diastolic. 11. participants with hypertension who are not on stable medication for at least 6 months. 12. has uncontrolled type 2 diabetes 13. concurrent treatment with urate lowering drugs (ulds). 14. prior exposure to any experimental or marketed uricase (eg, rasburicase \[elitek, fasturtec\], pegloticase \[krystexxa®\], pegadricase \[sel-212\]). 15. glucose-6-phosphate dehydrogenase (g6pd) deficiency or known catalase deficiency.

Keywords: uricase gout uric acid prx-115 hyperuricemia
a registry for people with lung cancer

Conditions: Lung Cancer; Lung Cancer Stage I

Summary: participants will complete questionnaires before surgery, between 2 to 4 weeks after surgery, and 6 months after surgery.


Eligibility criteria:
inclusion criteria: * age ≥18 years * clinical stage i tumor (ajcc 8th edition) suitable for segmentectomy, according to the treating thoracic surgeon o note: patients must undergo segmentectomy for a peripheral lesion ≤2 cm to be included in the primary analysis. individual ligation of the segmental artery(s) and segmental bronchus is the minimum definition for a segmentectomy. division of the segmental vein and intraoperative frozen section to assess surgical margins and n1 lymph nodes are strongly encouraged, but the absence of either is not a criterion for exclusion. * pathology of nsclc o tissue diagnosis of nsclc is not required before enrollment. a pathologic diagnosis of nsclc may be confirmed preoperatively with biopsy, intraoperatively with frozen section, or postoperatively on final pathology. other considerations: * patients with ground-glass opacities will have their tumor size recorded on the basis of the size of the solid component. * any non-lung cancer treated in the past with no obvious recurrence or ongoing treatment is not a criterion for exclusion. * the registry study will be monitored by thoracic surgery team at msk. * this study will be in collaboration with the thoracic surgical oncology group (tsog) of the american association for thoracic surgery. exclusion criteria: * actively receiving lung cancer treatment or a history of lung cancer in the previous 5 years * history of chemotherapy or radiation therapy for a previous lung cancer * synchronous secondary cancer in the lung or elsewhere in the body at the time of surgery * carcinoid tumors * history of other malignancies within the past 3 years, with the exception of non-melanoma skin cancer, superficial bladder cancer, and carcinoma in situ of the cervix * actively receiving treatment for other malignancies * cases of lobectomy in conjunction with segmentectomy from another lobe and ≥2 segmentectomies from different lobes either en bloc or separate will be excluded from the primary analysis. * multi-segmental resection from the same lobe is not a criterion for exclusion.

Keywords: lung cancer lung cancer stage 1 segmentectomy memorial sloan kettering cancer center 24-127
study of sacituzumab govitecan in participants with metastatic solid tumors

Conditions: Metastatic Solid Tumor

Summary: the goal of this clinical study is to learn more about the study drug, sacituzumab govitecan-hziy, in participants with metastatic (cancer that has spread) solid tumors.


Eligibility criteria:
key inclusion criteria: * individuals with the following histologically documented metastatic (m1, stage iv) or locally advanced solid tumors * nsclc (adenocarcinoma or scc) that has progressed after prior platinum-based chemotherapy and programmed death-(ligand) 1 (pd-(l)1) directed therapy * hnscc that has progressed after prior platinum-based chemotherapy and anti-pd-(l)1 directed therapy no more than 3 prior lines of systemic treatment is allowed * endometrial carcinoma that has progressed after prior platinum-based chemotherapy and anti-pd-(l)1 directed therapy no more than 3 prior lines of systemic treatment is allowed. * extensive stage sclc that has progressed after prior platinum-based chemotherapy and pd-(l)1 directed therapy. no more than one prior line of systemic treatment is allowed (re-challenge with the same initial regimen is not allowed) * eastern cooperative oncology group (ecog) performance status score of 0 or 1 * adequate hematologic counts without transfusional or growth factor support within 2 weeks of study drug initiation * adequate hepatic and renal function (crcl ≥30ml/min) * individual must have at least a 3-month life expectancy * have measurable disease by computed tomography (ct) or magnetic resonance imaging (mri) as per response evaluation criteria in solid tumors (recist) 1.1 criteria key exclusion criteria: * have had a prior anti-cancer biologic agent within 4 weeks prior to study day 1 or have had prior chemotherapy, targeted small molecule therapy, radiation therapy within 2 weeks prior to study day 1 * have not recovered (i.e., ≤ grade 1) from adverse events due to a previously administered agent * have previously received topoisomerase i inhibitors * have an active second malignancy * have known active central nervous system (cns) metastases and/or carcinomatous meningitis. individuals with previously treated brain metastases may participate provided they have stable cns disease for at least 4 weeks prior to the first dose of study drug and all neurologic symptoms have returned to baseline, have no evidence of new or enlarging brain metastases and are taking ≤20 mg/day of prednisone or its equivalent. all individuals with carcinomatous meningitis are excluded regardless of clinical stability * additional cohort specific exclusion criteria note: other protocol defined inclusion/exclusion criteria may apply.
should the joint capsule of the painful stiff shoulder be ruptured during intra-articular hydraulic distension?

Conditions: Adhesive Capsulitis

Summary: the purpose of the study is to compare the efficacy of intra-articular hydraulic distension (ihd) for the treatment of painful stiff shoulders between capsule-rupturing and capsule-preserving ihds.

the painful stiff shoulder (pss), or the adhesive capsulitis, involves stiff and contracted joint capsule from fibrosis in the glenohumeral joint. intra-articular hydraulic distension (ihd) enlarges the stiffened capsule by deforming it with excessive volume and pressure within the joint space. although ihd is one of the most common treatment options for the pss, the diversity of the ihd technique spans wide range. specifically, it is not generally agreed as for which, between capsule-rupturing and capsule-preserving ihds, is superior for pss treatment. capsule-preserving ihd might fail to infuse sufficient amount of fluid to avoid rupture, thus producing less satisfactory outcomes. however, we devised in our previous study a novel technique that enabled a physician to infuse the possible largest volume without rupturing the capsule. by employing the technique, we aim to compare the clinical efficacy of capsule-rupturing versus capsule-preserving ihds in patients with psss.

Eligibility criteria:
inclusion criteria: * shoulder discomfort for at least one month * limited range of motion of the glenohumeral joint in at least two directions exclusion criteria: * systemic inflammatory joint disease * radiological evidence of bony abnormality of the shoulder * full-thickness rotator cuff tear * acute systemic medical illness * history of major trauma or surgery involving the shoulder * contraindication to intra-articular, local anesthestic injection

Keywords: injections, intra-articular range of motion, articular pain
study to assess clearances and bio-compatibility of elisio dialyzer

Conditions: Chronic Kidney Disease

Summary: today, haemodialysis is a recognized standard treatment for patients with chronic kidney disease stage 5. during the haemodialysis treatment session, blood passes from the patient through the extracorporeal circuit and is then returned. the dialyzer represents the greatest surface are of the extracorporeal circuit, as dialysis treatment is essentially based on the removal of small molecular weight solutes down along a concentration gradient, and this depends upon surface area. the elisio-h dialyzer differs in design to our current standard dialyzer, the fx100, by having fibers of a greater internal diameter, which potentially allows more internal haemofiltration, leading to an improved clearance of larger molecular weight solutes. it is now thought that these so called "middle molecular weight" solutes are more important in contributing to the clinical condition termed azotaemia, rather than smaller solutes such as urea. the investigators therefore wish to study the clearance of middle sized molecules between the different dialyzers.

stable chronic kidney dialysis patients, currently dialyzing on the main royal free hospital dialysis unit will be asked to participate in the study. it is aimed to recruit 15 patients currently dialysing using the fresenius fx100 dialyzer, who have used fresenius polysulphone membranes for \> 3 months. during a mid week dialysis session, dialysis adequacy will be assessed by on line clearance, and samples of both blood and dialysate taken to assess, both clearances and bio-compatibility. thereafter patients would be switched to dialyse using the elisiotm-h dialyzer, but continue with the same dialysis prescription, and after 3 months, measurements repeated assessments primary clearances : on-line kt/v, dual pool kt/v, phosphate, b2microglobulin, cystatin c secondary serum :isoprostane generation complement activation platelet activation - coagulation activation - thrombophilic markers - other anticoagulation requirements \& clotted circuits erythropoietin requirements, phosphate control therapy crp

Eligibility criteria:
inclusion criteria: * 15 adult patients currently dialysing using the fresenius fx100 dialyzer, who have used fresenius polysulphone membranes for \> 3 months, who are stable and able to provide informed consent. exclusion criteria: * using other dialyzers, unable to provide informed consent, unstable on dialysis or have problematical vascular access

Keywords: solute clearances
study of association between maternal uric acid , maternal and fetal outcome in pregnant women with hypertension

Conditions: Uric Acid and Hypertension in Pregnancy

Summary: association of maternal uric acid with maternal condition and fetal outcome in pregnant women with hypertension.

association of maternal uric acid with maternal condition(renal function,liver function,...ect.) and fetal outcome(birth weight,apger score) in pregnant women with hypertension.

Eligibility criteria:
inclusion criteria: * age:18-40 years old * gestational age:28-42 weeks gestation singleton pregnancy of living fetus * non smoker exclusion criteria: * women who refuse the study * any medical or obstetric disorders especially d.m.,renal disease,hepatic, cardiac disorders or gout arthritis, other than hypertension if present. * previously elevated uric acid level. * hemolytic or sickle cell anemia,urinary tract infection. * use of diuretics or anti-inflammatory drugs.

Keywords: uric acid
awareness among hearing enhancement interventions and reimbursement criteria of hearing implants

Conditions: Awareness; Hearing Impairment; Otorhinolaryngologic Surgical Procedures; Implant

Summary: the following research questions will be investigated: what is the knowledge of medical interventions for moderate to severe hearing loss and what is the knowledge of the reimbursement criteria for hearing implants of otorhinolaryngologists in a secondary setting in brabant. this will be evaluated by means of a specific questionnaire that will be systematically gone over with the participants during an interview in the first and third phase. in a second phase, the investigators will investigate how the knowledge of medical interventions for moderate to severe hearing loss and the knowledge of the reimbursement criteria for hearing implants of otorhinolaryngologists in a secondary setting in brabant can be increased by training the otorhinolaryngologists in a secondary setting in brabant. in the third phase, the investigators will evaluate the knowledge of hearing implant interventions and reimbursement criteria among otorhinolaryngologists in a secondary setting.

in most developed economies, cochlear implants have been shown to be the most successful neuroprostheses for sensory moderate or severe neurosensory loss. these neuroprostheses are cost-effective with low complication rates. however, the literature indicates that there is a low level of awareness of the benefits of cochlear implants among the general population and among healthcare professionals. in addition, a lack of specific referral pathways has been reported. utilization rates for adult hearing aids in people with severe or profound loss are 70% to 90%, but uptake in adults for cochlear implants is less than 10%. therefore, the aim of this research project is to investigate the knowledge about medical interventions in moderate to severe hearing loss and the knowledge about reimbursement criteria of hearing implants of otorhinolaryngologists in a secondary setting in brabant. the study group will consist of a maximum of 100 geographically selected otorhinolaryngologists aged 25-70 years in a secondary setting in brabant. a subselection will be made from the reachable otorhinolaryngologists in the region of brabant. recruitment will be discontinued when a maximum of 100 otorhinolaryngologists has been reached. a specific questionnaire will be systematically reviewed with the participants during an interview in the first and third phase. there is no financial compensation for the participants.

Eligibility criteria:
inclusion criteria: * otorhinolaryngologists working in a secondary setting * dutch and french speaking exclusion criteria: * otorhinolaryngologists working in a tertiary setting attached to a university
brain activity changes after structured cognitive-motor exercise for people with stroke

Conditions: Stroke

Summary: to assess the effects of a dual-task exercise program on cognitive-motor interference during dual-task walking and the associated changes in brain activity.

stroke is one of the leading causes of chronic disability in hong kong and other parts of the world. mobility dysfunctions are among the most common impairments observed after stroke. restoration of mobility is also a top priority in rehabilitation goal-setting by stroke patients. in daily life, functional ambulation in the community requires the ability to maintain walking balance while simultaneously engaging in other attention-demanding tasks (i.e., dual-tasking), such as walking when holding a conversation, or crossing the street while attending to traffic signals. there is increasing evidence that performing a cognitive task in conjunction with a mobility task would cause more severe degradation of one or both tasks among stroke patients when compared with age-matched able-bodied individuals. this phenomenon, termed "cognitive-motor interference", should warrant detailed study, since it has an important impact on community-living among people with stroke.

Eligibility criteria:
inclusion criteria: * diagnosis of stroke confirmed by brain scan reports * community-living * stroke onset ≥ 6 months * aged 50 years or older * modified rankin scale 1-3 * capable of following verbal instructions * montreal cognitive assessment score ≥ 22 * ability to walk for 1 min independently with or without a walking aid * not receiving formal rehabilitation elsewhere exclusion criteria: * other neurological disorders * pain or other comorbidities that seriously affect the ability to walk * contraindications to exercise (e.g., angina).

Keywords: dual-task training cognitive-motor interference
pleural carcinomatosis tissue banking

Conditions: Pleural Effusion, Malignant

Summary: malignant pleural effusion is a common evolution of various cancers and is associated with poor prognosis and quality of life. about 28% of patients with primary malignancy will develop pleural metastasis. malignant pleural effusion mostly occurs in lung, breast, ovarian and gastric cancers. median survival ranges from 3 to 13 months according to primary malignancy. currently, the therapeutic approach is mainly palliative with videothoracoscopic talc pleurodesis or indwelling pleural catheters insertion eventually associated with systemic chemotherapy if patient's general condition allows. in a early-disseminated tumor cells profile, metastatic cells can accumulate alterations at a distant site and have a different profil from the original tumor cells. metastatic cells can also accumulate alterations in the course if systemic treatments. consequently, they may respond differently to drugs. recently, egfr mutations and alk status discordance between primary tumors and pleural metastases have been demonstrated in a significant portion of lung adenocarcinomas. these studies, realized on malignant pleural effusion isolated cells, enabled us to hypothesize a possible intratumoral heterogeneity within pleural metastases, but no study has been carried out on pleural tissue. our aim is to create a biocollection with tissues from pleural carcinomatosis in order to subsequently allow multiomics and bioinformatics analyzes and to characterize a possible intratumoral heterogeneity in pleural metastasis.


Eligibility criteria:
inclusion criteria: * male or female over 18 years old * malignant pleural effusion with or without prior histological or cytological diagnosis * patient eligible for a pleural biopsy for diagnostic purposes and validated in a multidisciplinary consultation meeting * having given their free and informed writing consent * affiliated to a social security system or assimilated exclusion criteria: * malignant pleural mesothelioma * contraindication to general anesthesia * pregnant or breastfeeding woman, or is of child bearing potential and who did not agree to use highly effective methods of birth control throughout the study. * patient participating in a interventional study likely to interfere with this study * patient benefiting from a legal protection measure (guardianship or curatorship)

Keywords: malignant pleural effusion pleural carcinomatosis pleural metastasis tissue banking
intravenous immunoglobin transfusion in preterm infants with encephalopathy of prematurity

Conditions: Preterm Infants

Summary: infection and inflammation is related to increased encephalopathy of prematurities.

animal studies have verified intravenous immunoglobin can reduce brain injury. however, no studies in preterm infants were reported.

Eligibility criteria:
inclusion criteria: * preterm infants with encephalopathy exclusion criteria: * refuse the participate in the trial
extended perioperative administration of fibrinolysis inhibitors after cardiac surgery

Conditions: Thoracic Surgery; Heart Diseases; Fibrinolysis Shutdown

Summary: priority is a pragmatic, multi-center, cluster crossover trial that aims to evaluate whether implementing a policy of routine extended (intraoperative and 4 hour after transfer to icu) use of fibrinolysis inhibitors leads to a decrease in post-operative blood transfusion compared to a policy that only involves intraoperative use.

routine use of fibrinolysis inhibitors is strongly recommended in cardiac surgery (recommendation level 1a). however, despite numerous studies on the pharmacodynamics and clinical effects of these drugs, there is still no consensus on the optimal dose and dosage regimen. as a result, there is wide variability in the use of fibrinolysis inhibitors across different clinics. several studies have shown that peak activation of fibrinolysis occurs during cardiopulmonary bypass. however, elevated levels of markers of fibrinolytic activity in the blood plasma are observed for at least 2 hours after surgery and 4 hours after heparin neutralization. this suggests the potential for extended use of fibrinolysis inhibitors after surgery. there have been limited attempts to investigate the effectiveness of postoperative administration of fibrinolysis inhibitors, and these studies have been conducted on small samples or with retrospective designs. the authors of these studies were unable to identify the benefits of postoperative administration in terms of reducing bleeding risk and the need for blood transfusions. however, postoperative infusion of fibrinolysis inhibitors demonstrated a comparable safety profile. there is evidence suggesting that repeated administration of fibrinolysis inhibitors after cardiopulmonary bypass, rather than a single dose at the beginning of surgery, may be more beneficial. due to uncertainty regarding the best approach (routine extended use of fibrinolysis inhibitors or no routine extended use of fibrinolysis inhibitors), we will compare the effects of a hospital policy that includes routine administration of fibrinolysis inhibitors 4 hours after surgery to a policy that avoids routine postoperative administration. the comparison will focus on the blood transfusion requirement during hospitalization among patients undergoing open heart surgery.

Eligibility criteria:
inclusion criteria: 1. a hospital that performs a minimum of 250 open heart interventions per year. 2. consent from hospital physicians regarding the prophylactic use of fibrinolysis inhibitors (more than 95% of physicians involved in the treatment of adult patients (\>18 years) agree to adhere to the strategy of using fibrinolysis inhibitors as prescribed by the study protocol). exclusion criteria: * hospital does not meet inclusion criteria